Stock quote - News

Avacta Group
AVCT: 22.25 0.00 ( 0.00 %) delayed: 16:57PM


  • Avacta to submit clinical trial application in early 2020
    Monday 03 Jun 2019 15:06

    Biotherapeutics and research reagent developer Avacta Group said that it was planning to submit an application early in 2020 to conduct a clinical study in patients with selected solid tumours. Avacta's tumour microenvironment activated drug conjugates, or TMAC, were a ground-breaking new form...
    Read more

  • ModernaTX takes up option to develop, sell Avacta's affimer technology
    Monday 04 Feb 2019 08:32

    Avacta Group said Monday that ModernaTX had exercised its option to enter into an exclusive licensing agreement with respect to certain Affimer molecules that had been generated through collaboration between the two companies. Under the terms of the agreement, Avacta was in line to receive...
    Read more

  • Director Deals - Avacta Group PLC (AVCT)
    Wednesday 02 Jan 2019 09:25

    Tony Gardiner, Executive Director, bought 8,196 shares in the company on the 31st December 2018 at a price of 30.50p. The Director now holds 8,196 shares. Story provided by StockMarketWire.com Director deals data provided by www.sharesmagazine.co.uk
    Read more

  • Avacta appoints Jose Saro as chief medical officer
    Wednesday 12 Dec 2018 14:38

    Avacta Group said it had appointed Jose Saro as its new chief medical officer. Saro joined the group from Roche, where he was senior translational medicine leader at an innnocation centre in Zurich. He had also worked as a senior executive at Bristol Myers Squibb. At 2:38pm: (LON:AVCT) Avacta...
    Read more

  • Avacta forms therapeutics development pact with South Korea's LG Group
    Monday 10 Dec 2018 14:09

    Avacta Group said it had formed a development partnership and license agreement with a unit of South Korea's LG Group for biotherapeutics in several disease areas. The agreement provided for upfront and near-term milestone payments, plus longer-term clinical development milestones, totalling...
    Read more

  • Avacta to present pre-clinical development data at Lisbon conference
    Monday 12 Nov 2018 13:43

    Biotherapeutics and reagents developer Avacta Group said chief scientific officer Amrik Basran would present at a conference in Lisbon this week. Basran would on Wednesday present recent data from pre-clinical development of the company's lead therapeutic programme, at the Protein Engineering...
    Read more

  • Avacta Group losses widen as R&D investment jumps 31%
    Tuesday 02 Oct 2018 09:39

    Biotherapeutics and reagents producer Avacta Group said Tuesday annual losses widened following an acceleration in research and development investment. For the 12 months to 21 July, pre-tax losses widened to £10.39m from £7.89m and revenue rose 1.02% to £2.76m. Profits were weighed down by a...
    Read more

  • Avacta forms collaboration pact with Tufts University in Boston
    Tuesday 24 Jul 2018 14:14

    Biotherapeutics and reagents developer Avacta Group said it had formed a co-development partnership with Bach BioSciences, a company commercialising research conducted at Tufts University School of Medicine, Boston. The collaboration would develop a new class of drug conjugate therapies with a...
    Read more

  • Avacta appoints Eliot Forster as its new chairman
    Monday 11 Jun 2018 14:55

    Avacta Group said it had appointed Eliot Forster as its new chairman, replacing Trevor Nichols, who would remain as a non-executive director. Forster was most recently chief executive of immuno-oncology biotech Immunocore. At 2:55pm: (LON:AVCT) Avacta Group PLC share price was 0p at 34p...
    Read more

  • Avacta hails encouraging results from FIT Biotech collaboration
    Tuesday 22 May 2018 14:36

    Avacta Group said a research collaboration with Finland's FIT Biotech had produced 'very encouraging' data relating to its biotherapeutics and reagents. The proof-of-concept study showed sustained production of the company's Affimer molecules by the muscle tissue of mice. This was achieved...
    Read more

  • Avacta Group net losses widen as costs rise
    Monday 16 Apr 2018 08:29

    Avacta Group, reported Monday a wider half year net loss of £4m, compared with a loss of £3.4m the previous the year, weighed by an increase in administration costs. Administration costs rose to £4.00m from £3.50m, as the firm's Life Sciences division, in particular the US business development...
    Read more

  • Director Deals - Avacta Group PLC (AVCT)
    Tuesday 13 Mar 2018 12:30

    Prof Alastair Smith, Chief Executive Officer, bought 35,800 shares in the company on the 13th March 2018 at a price of 41.92p. The Director now holds 606,309 shares. Story provided by StockMarketWire.com Director deals data provided by www.sharesmagazine.co.uk
    Read more

  • Avacta in line with market forecasts
    Thursday 18 Jan 2018 07:31

    Avacta expects revenue, operating losses and cash balances for the six months ending 31 Jan to be in line with market forecasts. The group said it was making strong progress with in-house programmes and solid progress with its partners. Group chief executive Dr Alastair Smith said: 'I am very...
    Read more

  • Avacta agrees development partnership with Glythera
    Monday 15 Jan 2018 07:04

    Avacta Group and Glythera have agreed the terms of a licensing deal which will allow them to develop drug conjugates using their combined technologies. Avacta said a successful proof-of-concept study had shown that Affimers have key technical benefits for drug conjugates. The detailed terms...
    Read more

  • Avacta to host capital markets day
    Monday 08 Jan 2018 09:26

    Avacta Group will host a capital markets day for financial analysts and institutional investors at finnCap's offices, 60 New Broad St, London, EC2M 1JJ, on 7 Feb from 2 p.m. to 4 p.m. The event will begin with a non-technical corporate update by chief executive Alastair Smith on strategy, key...
    Read more

  • Avacta CEO to present at Biotech Showcase
    Wednesday 03 Jan 2018 07:38

    Avacta Group chief executive Dr Alastair Smith will be presenting at the annual Biotech Showcase which is being held in San Francisco on 8-10 Jan. Smith will outline the key benefits of the group's Affimer technology as a therapeutic protein platform and update the meeting on progress within...
    Read more

  • Avacta schedules AGM
    Monday 04 Dec 2017 14:26

    Avacta Group has confirmed that the Company intends to hold its Annual General Meeting on 18 January. At 2:26pm: (LON:AVCT) Avacta Group PLC share price was 0p at 65p Story provided by StockMarketWire.com
    Read more

  • Avacta sets up SIP, issues shares
    Thursday 30 Nov 2017 15:00

    Avacta Group said it has established an HMRC approved Share Incentive Plan for all eligible UK employees. As part of the SIP Award Scheme, shares of up to a value of £3,000 per employee will be issued at the prevailing middle market price at the close of business the day before an award to all...
    Read more

  • Covance to present Affimer data at forum says Avacta
    Wednesday 15 Nov 2017 08:14

    Avacta, the developer of Affimer biotherapeutics and reagents, has announced that Covance will be presenting Affimer data from a joint study at the European Bioanalysis Forum in Barcelona on 15-17 Nov. Avacta said Covance will be presenting data that highlights the validation of Affimer as a...
    Read more

  • Avacta to present at PEGS Europe
    Monday 13 Nov 2017 07:52

    Avacta Group chief scientific officer, Dr Amrik Basran, will be presenting an update on the Affimer therapeutics programmes at the Protein and Antibody Engineering Summit which starts in Lisbon today. Basran will present recent progress in the Affimer therapeutic programmes and will focus on...
    Read more

  • Record Year for Affimers in scientific publications, says Avacta
    Tuesday 24 Oct 2017 07:41

    Avacta Group, the developer of Affimer biotherapeutics and reagents, said 2017 had been a record year for scientific publications using Affimer reagents, with nine scientific papers reporting the work of leading groups world-wide. It said two recent papers from the world-renowned laboratory of...
    Read more

  • Avacta to present at Shares Spotlight Evening
    Thursday 12 Oct 2017 07:47

    Avacta Group chief executive Alastair Smith will be presenting at the Shares Spotlight Evening on 19 Oct at the Novotel Hotel, Tower Bridge, 10 Pepys Street, London, EC3N 2NR. The event, which begins at 18:00hrs, provides an opportunity for investors to hear about the group's Affimer...
    Read more

  • Avacta to present at the Shares Spotlight Evening in London on 19 October 2017
    Tuesday 10 Oct 2017 09:55

    Looking for new investment ideas and want to meet senior directors of listed UK companies? Come along and join Shares and AJ Bell on Thursday 19 October 2017 at their evening event in London and meet Avacta (AVCT), Custodian REIT (CREI), Non-Standard Finance (NSF), Savannah Resources (SAV) and...
    Read more

  • Avacta CTO to present at US conference
    Tuesday 10 Oct 2017 08:00

    Avacta chief technology officer, Dr Matt Johnson is presenting at the Annual Biomarkers & Precision Medicine Congress in San Diego which ends tomorrow. Johnson will be presenting new Affimer applications including data from a collaboration with Covance, part of LabCorp, one of the world's...
    Read more

  • Avacta research collaboration with FIT Biotech
    Thursday 05 Oct 2017 08:56

    Avacta Group, the developer of Affimer biotherapeutics and reagents, has initiated a research collaboration with FIT Biotech Oy to assess the effectiveness of developing gene therapies using Avacta's Affimer technology combined with FIT Biotech's gtGTU platform. Avacta Group chief executive...
    Read more

  • Avacta revenues rise but losses widen
    Wednesday 04 Oct 2017 07:10

    Avacta's revenues rose by 26% to £2.74m in the year to the end of July with Avacta Life Sciences revenue up at £1.15m (2016: £0.70m), in line with market expectations and Avacta Animal Health revenue of £1.59m (2016: £1.46m). The loss from continuing operations rose to £6.37m (2016: £4.65m) and...
    Read more

  • Avacta establishes US business development team
    Monday 02 Oct 2017 07:32

    Avacta Group has established a commercial team of three people in the US including the appointment of Dr Matthew Vincent as vice-president therapeutics business development. It said: 'In order to exploit the rapidly growing interest in Avacta's proprietary Affimer alternative to antibodies, and...
    Read more

  • Director Deals - Avacta Group PLC (AVCT)
    Monday 21 Aug 2017 15:45

    Prof Alastair Smith, Chief Executive Officer, bought 33,225 shares in the company on the 21st August 2017 at a price of 74.50p. The Director now holds 570,509 shares. Story provided by StockMarketWire.com Director deals data provided by www.directorsholdings.com
    Read more

  • Avacta revenues rise
    Monday 07 Aug 2017 08:07

    Avacta Group expects revenues for the year ended 31 July to be 27% up on last time at £2.75m, in line with market forecasts. The group said the cash position was well ahead of market expectations at £13m (2016: £19.5m) and the loss before interest and taxation was expected to be in line with...
    Read more

  • FLASH: Avacta revenues rise
    Monday 07 Aug 2017 07:11

    Story provided by StockMarketWire.com
    Read more

  • Avacta to be granted patent in China
    Wednesday 10 May 2017 09:53

    Avacta Group has announced that the principal patent protecting the Affimer technology had been accepted for grant in China. Avacta said that on issuance, this patent would extend coverage of Avacta's intellectual property into another potentially large market for the company. It said that...
    Read more

  • FLASH: Avacta to be granted patent in China
    Wednesday 10 May 2017 07:05

    Story provided by StockMarketWire.com
    Read more

  • Moderna releases Phase I trial data for mRNA technology
    Monday 08 May 2017 13:32

    Avacta Group has confirmed that Moderna has disclosed Phase I trial data for its mRNA technology. It says this is the first public evidence that it works, which meaningfully de-risks the partnership plans to deliver Affimer therapeutics using mRNA. Background: Avacta is the proprietary owner...
    Read more

  • Avacta CEO to present at Hardman forum
    Friday 05 May 2017 09:37

    Avacta Group chief executive Alastair Smith will be presenting at the Hardman Private Investor Forum in London at the University of Liverpool, 33 Finsbury Square, EC2A 1AG, on 9 May. The group said the evening event - which would begin with registration at 17:30 - would provide an opportunity...
    Read more

  • Avacta agrees exclusive deal with global diagnostics firm
    Monday 24 Apr 2017 08:20

    Avacta Group has confirmed that an evaluation of its Affimer technology by a large, global diagnostics developer has concluded successfully and that the third party had taken exclusive rights to several Affimer reagents for an undisclosed sum. Avacta has adopted a licensing business model for...
    Read more

  • Avacta to present at Shares Spotlight Evening
    Wednesday 19 Apr 2017 07:56

    Avacta chief executive Alastair Smith will be presenting at the Shares Spotlight Evening on 26 April at the Novotel Hotel, Tower Bridge, London, EC3N 2NR. The group said this provided an opportunity for investors to hear about the company's Affimer technology, its development plans and to meet...
    Read more

  • FLASH: Avacta to present at Shares Spotlight Evening
    Wednesday 19 Apr 2017 07:05

    Story provided by StockMarketWire.com
    Read more

  • Avacta Plc to present at the Shares Spotlight Evening in London on 26 April 2017
    Wednesday 05 Apr 2017 12:01

    Shares are pleased to present Ariana Resources (AAU), Avacta (AVCT) and eg solutions (EGS) at their event in London on Wednesday 26 April 2017. The evening event provides an opportunity for board directors from these three companies to make a presentation about their company and update existing...
    Read more

  • Avacta revenues rise
    Monday 03 Apr 2017 08:10

    Avacta Group's half year revenues increased 20% to £1.3m and comprised of £0.5m from Avacta Life Sciences and £0.8m from Avacta Animal Health. The developer of Affimer biotherapeutics and research reagents said operating losses rose to £3.9m from £2.0m and pre-tax losses of £3.8m were up from...
    Read more

  • FLASH: Avacta revenues rise
    Monday 03 Apr 2017 07:09

    Story provided by StockMarketWire.com
    Read more

  • Avacta CEO to present at UK Investor Show
    Wednesday 22 Mar 2017 09:27

    Avacta Group chief executive Alastair Smith will be presenting at the UK Investor Show at the QE2 Centre, Westminster, on 1 April. Members of Avacta Group's management team will be at stand 37 during the day and Smith will be presenting at 16:00 in the Winnifrith-Britten room. At 9:27am:...
    Read more

  • Avacta sees substantial progress
    Friday 20 Jan 2017 07:40

    Avacta Group has made substantial progress in the past year in demonstrating the performance and differentiation of its Affimer technology in key applications, shareholders at the annual general meeting today will be told. Avacta said the custom Affimer order book had grown 70% YOY and half...
    Read more

  • FLASH: Avacta sees substantial progress
    Friday 20 Jan 2017 07:04

    Story provided by StockMarketWire.com
    Read more

  • Avacta CEO to present at London forum
    Wednesday 11 Jan 2017 09:48

    Avacta Group chief executive Alastair Smith will be presenting at the London Growth and Innovation Forum on 31 January at the Business Design Centre, London. The forum is a one-day investor exhibition showcasing innovative technology led companies. Avacta Group's management team will be at...
    Read more

  • Avacta Plc to present at the Growth and Innovation Forum 2017 in London on 31 January 2017
    Friday 06 Jan 2017 15:39

    Avacta Plc to present at the Growth and Innovation Forum 2017 in London on 31 January 2017 Alastair Smith, CEO of Avacta Plc (AVCT) [LSE:AVCT] the developer of Affimer biotherapeutics and research reagents, is to present at the Growth and Innovation Forum 2017 in London on 31 January 2017. The...
    Read more

  • Avacta to present positive Affimer data
    Wednesday 23 Nov 2016 07:38

    Avacta Group will present data that highlights the competitive performance of Affimers in affinity separation applications at bioProcessUK in Newcastle on 23-24 November. Affinity separation is one of three non-therapeutic applications that the company highlighted in its strategic plan...
    Read more

  • FLASH: Avacta to present Affimer performance data
    Wednesday 23 Nov 2016 07:02

    Story provided by StockMarketWire.com
    Read more

  • Cancer expert joins Avacta scientific advisory board
    Monday 07 Nov 2016 09:02

    Avacta Group, the developer of Affimer biotherapeutics and research reagents, has appointed Professor Gerard Evan, FRS, to its therapeutics scientific advisory board. Avacta says Evan brings world-leading expertise in immuno-oncology and cancer stem cell research to support the froup's...
    Read more

  • FLASH: Cancer expert joins Avacta scientific advisory board
    Monday 07 Nov 2016 07:05

    Story provided by StockMarketWire.com
    Read more

  • Avacta cell therapy research collaboration in US
    Wednesday 02 Nov 2016 07:40

    Avacta Group has announced a research collaboration with Memorial Sloan Kettering Cancer Center (MSK) to evaluate the use of Avacta's Affimer technology in novel CAR-T cell-based immunotherapy. CAR-T immunotherapy is a form of cancer treatment in which the patient's own immune system T cells...
    Read more

Page 1 |

Risk warning: Remember the price of shares can go down as well as up, and you are not guaranteed to get back the amount that you originally invested.
Click here to read the full warning.